(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 4, 1999, Pages 533-538

  Nomura, Masahiro ^a   Kinoshita, Susumu ^a   Satoh, Hiroya ^a   Maeda, Toshio ^a   Murakami, Koji ^a   Tsunoda, Masaki ^a   Miyachi, Hiroyuki ^a   Awano, Katsuya ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTIDIABETIC AGENT; PIOGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, OBESE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINEDIONES; THIAZOLIDINES; TRIGLYCERIDES;

ANIMALIA;

EID: 0033593916     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00039-6     Document Type: Article

References (16)

1. 1. Porte, D. Jr.; Schwartz, M. W. Science. 1996, 272, 699.
2. 2 a)Feldt-Rasmussen, B.; Mathiesen, E.R. ; Deckert, T. Lancet 1986, II, 1300.
3. b) Dahl-Jorgensen, K.; Brinchmann-Hansen, O.; Hansen, K. F.; Ganes, T.; Kierulf, P.; Smeland, E.; Sandvik, L.; Aagenaes, O. Br. Med. J. 1986, 293, 1195.
4. 3. Jaspan. J. B. Metabolism. 1987, 36 (Suppl. 1), 22.
5. 4. The Diabetes Control and Complications Trial Research Group. New Engl. J. Med. 1993, 329, 977.
6. 5. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Chem. Pharm. Bull. 1982, 30, 3563.
7. 6. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa , Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. J. Med. Chem, 1989, 32, 421.
8. 7. a) Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka , C.; Oi, S.; Sohda, T. Chem. Pharm. Bull. 1991, 39, 1440.
9. b) Sugiyama, Y.; Taketomi, S.; Shimura, Y.; Ileda, H.; Fujita, T. Arzneim. Forsch. Drug. Res. 1990, 40, 263.
10. 8. Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. Bioorg. Med. Chem. Lett. 1994, 4, 1181.
11. 9. Stevenson, R W.; Hutson, N. J.; Krapp, M. N.; Volkmann, R. A.; Holland, G. F.; Eggler, J. F.; Clark, D. A.; McPherson, R. K.; Hall, K. L.; Danbury, B. H.; Gibbs, E. M.; Kreutter, D. K. Diabetes. 1990, 39, 1218.
12. 10. Troglitazone is being marketed in the United States as Rezulin and in Japan as Noscal.
13. 11. Johnson, J. R. Org. React. 1942, 1, 210.
14. 12. Rondestvedt, C. S. Org. React. 1976, 24, 225.
15. 13. Lehmann, J. M.; Moore, L B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson , T. M.; Kliewer, S. A. J. Biol. Chem. 1995, 270, 12953.
16. 14. Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; Akanuma, Y.; Yazaki, Y.; Kadowaki, T.; Diabetes. 1998, 47, 1841.